HC Wainwright Predicts Higher Earnings for Integra Resources
Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for shares of Integra Resources in a ...
HC Wainwright Cuts Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $11.00
Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) had its price target trimmed by HC Wainwright from $15.00 to $11.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage ...
Co-Diagnostics price target lowered to $1 from $1.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following ...
Acumen price target lowered to $11 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Acumen (ABOS) to $11 from $15 and keeps a Buy rating on the shares. The firm says completion ...
Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa
Diagnostics' Q4 2024 earnings insights, FDA resubmissions, TB & HPV test pipelines, and international market growth plans.
TMCnet3d
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...
Fintel on MSN17d
HC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy Recommendation
Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...
Investing17d
H.C. Wainwright maintains Neutral on Lyell Immunopharma stock
On Thursday, H.C. Wainwright reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) shares, with a steady price target of $1.00. The stock, currently trading at $0.67, has experienced ...
Investing17d
H.C. Wainwright maintains Neutral on Lyell Immunopharma stock
On Thursday, H.C. Wainwright reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) shares, with a steady price target of $1.00. The stock, currently trading at $0.67, has experienced ...
Investing19d
H.C. Wainwright maintains Buy on Viking Therapeutics stock
On Tuesday, H.C. Wainwright reaffirmed its Buy rating on Viking Therapeutics (NASDAQ:VKTX), with a steady price target of $102.00. Currently trading at $27.96, the stock has significant upside ...
Yahoo Finance19d
H.C. Wainwright says Novo results support Viking obesity potential
H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...
CoinDesk20d
U.S. Strategic Bitcoin Reserve a 'Monumental Endorsement' of the Crypto: H.C. Wainwright
The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest cryptocurrency, broker H.C. Wainwright said in a research report Monday.